• Diabetes Connections | Type 1 Diabetes

  • De: Stacey Simms
  • Podcast
Diabetes Connections | Type 1 Diabetes  Por  arte de portada

Diabetes Connections | Type 1 Diabetes

De: Stacey Simms
  • Resumen

  • The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
    Stacey Simms Media 2015-2024
    Más Menos
Episodios
  • In the News... Dexcom to Apple Watch, Metformin during pregnancy, Mounjaro shortage update... and more!
    Jun 7 2024
    It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom goes Direct to Watch in the US, Abbott gets FDA okay for its OTC CGM, new study about metformin during pregnancy, an update on semaglutides, JDRF changes its name, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week – some CGM news… Dexcom announces Direct to Watch is here in the US. From the release: Using its own dedicated Bluetooth connection, Dexcom G7 sends glucose information and personalized alerts right to a user’s Apple Watch. Dexcom G7 is the only CGM system that can display glucose on multiple devices simultaneously and independently, including on a smartphone, smart watch, receiver or connected automated insulin delivery system.‡ Apple products are built with strong privacy protections and users have control over their data in the Health app. (If you like to keep track of these things, we are just over 7 years since the official announcement this was going to happen) XX FDA approves Abbot’s over-the-counter continuous glucose monitoring system. It’s called Lingo and comes a couple of months after Dexcom won clearance for its Stelo over-the-counter CGM. Abbott has been selling Lingo in the UK as more of a lifestyle device – not aimed at people with diabetes. They call it a consumer biowearable designed to help people make decisions about their overall health and wellness; Lingo is not intended for use in diagnosis, treatment or management of a disease or medical condition. No word yet on exactly what kind of app they’ll launch here in the US or if it will be marketed toward people with diabetes like the Libre currently is.. just as an OTC option. While it seems like the same hardware, the company has not confirmed that. https://www.drugdeliverybusiness.com/abbott-wins-fda-clearance-for-its-lingo-otc-glucose-monitor/ XX New study looking at the use of continuous glucose monitors (CGMs by rural children and adolescents living with type 1 diabetes. Previous studies examining the use of CGMs by children relied on prescription records to identify use of these devices, but just because someone is prescribed a CGM does not mean that they use one; barriers such as cost can stand in the way. this study instead identified use of these devices according to billing codes for the interpretation of CGM readings by the provider. The results unearthed a sizeable disparity. Those living in rural areas were significantly less likely to use a CGM than those in urban areas, even after adjusting for sex, race or ethnicity and insurance type. Specifically, compared with youth living in urban areas, the use of CGMs was 31% lower for children and adolescents living in small rural towns, and 49% lower for those living in isolated rural towns. The gap between rural and urban patients persisted across the four years of the study, even as the use of CGMs increased for all patient types during this time. These results are also relevant to people with type 2 diabetes who require insulin, Tilden said. The results also revealed that non-White patients, those who had public insurance and patients who lived in areas with a higher NPI all were less likely to use CGMs. More research is needed to explore the reasons for these disparities, but Tilden said they likely are a function of such issues as cost, reduced internet access, which CGMs require to relay their data, and distance from clinics and Medicaid-contracted pharmacies. The next step is figuring out how to eliminate those disparities. These researchers are seeking funding to design an intervention that uses telemedicine and partners with a network of 35 clinics across Kansas to deliver specialty care to diabetes patients in rural areas. https://www.kumc.edu/about/news/news-archive/...
    Más Menos
    11 m
  • How close are we to glucose-responsive insulin? An update from Sensulin’s CEO
    Jun 4 2024

    We’ve been hearing about smart insulin for a long time. This refers to an insulin that would react to glucose levels and adjust by itself with no external device, like a CGM, needed. You’d inject and let the insulin do the work.

    I’m talking to Sensulin CEO Mike Moradi about where their version of this amazing sounding technology stands, his family connections that really feeds his passion here, and what has to happen to get glucose-responsive insulin into the hands of people who could benefit.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Find out more about Moms' Night Out - registration is open for Denver and Philadelphia!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com

    Más Menos
    30 m
  • Disney DAS pass changes, plus GlucosePath & Catalyst studies
    May 28 2024

    Disney very recently made some changes to their Disability Access Services program – often referred to as a DAS pass at Disney World and Disney Land. We’re going to talk about why this happened, what it means for you, and what else is going on at Disney.

    Note: this interview was taped BEFORE the changes took place.

    More about Len Testa's Touring Plans here

    More about the DAS changes here

    We’re also spending some time talking about a new service for doctors called Glucosepath and about a new surprising study about cortisol and diabetes. I’ll also explain how these two guests can talk about all of these issues..

    Len Testa is co host of the fabulous Disney Dish podcast and the creator of Touring Plans the app and service of The Unofficial Guides to Walt Disney World, Disneyland and Disney Cruise Line. Testa is all about the math of theme parks – his guides are there to maximize the magic as he says – to make your waits shorter and save money – and it’s all based on calculations from his team.

    He teamed up with endocrinologist Dr. Bradly Eilerman to create GlucosePATH which uses computer science and clinical data to evaluate every possible treatment option, using data from the patient, FDA, and peer-reviewed journals, in just a few seconds.

    Dr. Eilerman also talks about the Catalyst study which looks at people with type 2 diabetes and measures cortisol.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Find out more about Moms' Night Out - registration is open for Denver!

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Edgepark Medical Supplies

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    Drive research that matters through the T1D Exchange

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Twitter

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com

    Más Menos
    38 m

Lo que los oyentes dicen sobre Diabetes Connections | Type 1 Diabetes

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.